8.75
Fulcrum Therapeutics Inc stock is traded at $8.75, with a volume of 344.22K.
It is down -2.67% in the last 24 hours and up +25.00% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$8.99
Open:
$9.04
24h Volume:
344.22K
Relative Volume:
0.55
Market Cap:
$473.30M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-5.538
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-7.89%
1M Performance:
+25.00%
6M Performance:
+225.28%
1Y Performance:
+151.44%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FULC
Fulcrum Therapeutics Inc
|
8.75 | 486.28M | 2.81M | -97.34M | -91.47M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-12-24 | Downgrade | Stifel | Buy → Hold |
Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
Sep-25-23 | Initiated | Goldman | Neutral |
Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
Aug-22-23 | Upgrade | Stifel | Hold → Buy |
May-04-23 | Downgrade | Goldman | Buy → Neutral |
Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-09-23 | Downgrade | Stifel | Buy → Hold |
Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
Nov-15-22 | Initiated | Goldman | Buy |
Mar-08-22 | Initiated | Oppenheimer | Outperform |
Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-22-21 | Initiated | Credit Suisse | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Oct-16-20 | Initiated | Piper Sandler | Overweight |
Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Jun-17-20 | Initiated | BTIG Research | Buy |
Oct-03-19 | Initiated | H.C. Wainwright | Buy |
Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Fulcrum Therapeutics Inc. stock outlook for YEARJuly 2025 Breakouts & Capital Protection Trading Alerts - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stockJuly 2025 Spike Watch & Precise Swing Trade Entry Alerts - newser.com
Is Fulcrum Therapeutics Inc. stock poised for growthTrend Reversal & Low Risk Entry Point Guides - newser.com
How to build a dashboard for Fulcrum Therapeutics Inc. stock2025 Short Interest & Reliable Price Action Trade Plans - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockStop Loss & Daily Stock Momentum Reports - newser.com
Fulcrum Therapeutics Inc. stock volume spike explainedJuly 2025 Closing Moves & Free Community Supported Trade Ideas - newser.com
What data driven models say about Fulcrum Therapeutics Inc.’s futureWeekly Stock Analysis & AI Driven Stock Movement Reports - newser.com
What is Leerink Partnrs' Estimate for FULC FY2027 Earnings? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partnrs Has Negative Outlook of FULC FY2027 Earnings - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - MSN
FULCFulcrum Therapeutics Latest Stock News & Market Updates - Stock Titan
Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com
What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com
Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com
Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat
How supply chain issues affect Fulcrum Therapeutics Inc. stockJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com
Published on: 2025-10-05 20:19:33 - newser.com
Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com
Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 52-Week HighTime to Buy? - MarketBeat
Oppenheimer reiterates Outperform on Fulcrum Therapeutics stock ahead of data - Investing.com Canada
What analysts say about Fulcrum Therapeutics Inc stockSwing Trading Watchlist & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatments - MSN
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):